FRESENIUS KABI USA LLC

Trade (domestic/foreign)

Medical Device Safety Biosimilar Tariffs and USPTO Proposed Rule PTAB Proposed Rule - Restrict Use of IPR FY27 Appropriations: Domestic Production of Essential Medicines; Chemical-free Medical Devices Federal Procurement Preferences for Domestic Medicines Clinical Trials for Biosimilars; Interchangeability Biosimilar Market Entry through Regulatory Streamlining Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP) Industrial Base Management and Supply Chain (IBMSC)

TargetedSENATE · HOUSE OF REPRESENTATIVES · White House Office · U.S. Trade Representative (USTR) · Commerce, Dept of (DOC) · Health & Human Services, Dept of (HHS) · Food & Drug Administration (FDA)

Medicare/Medicaid

CMS Preference for Domestic Essential Medicines Net Elective Cost Policy: PBM Reform Through Bid Transparency

TargetedSENATE · HOUSE OF REPRESENTATIVES · White House Office · Labor, Dept of (DOL) · Centers For Medicare and Medicaid Services (CMS)

Health Issues

S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act S. 2296: National Defense Authorization Act (NDAA) for Fiscal Year 2026 Biosimilar Tariffs and USPTO Proposed Rule PTAB Proposed Rule - Restrict Use of IPR Medical Device Safety FDA Streamlining FY27 Appropriations: Domestic Production of Essential Medicines; Chemical-free Medical Devices Clinical Trials for Biosimilars; Interchangeability Biosimilar Market Entry through Regulatory Streamlining FY27 National Defense Authorization Act - Domestic Production of Essential Medicines CMS Preference for Domestic Essential Medicines Federal Procurement Preferences for Domestic Medicines Ancillary Product Patent Reform Net Elective Cost Policy: PBM Reform Through Bid Transparency Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP) Industrial Base Management and Supply Chain (IBMSC) Procurement